SCHEMBL1011700

SCHEMBL1011700

COc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1

nearest known ligand 0.87

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.87
CYP2D6 P10635 4/20 0.87
FAAH O00519 16/20 0.72
GABRA1 P14867 1/20 0.72
ADRA2C P18825 1/20 0.72
CNR1 P21554 1/20 0.72
HTR2A P28223 1/20 0.72
HTR2C P28335 1/20 0.72
CNR2 P34972 1/20 0.72
HTR2B P41595 1/20 0.72
TMEM97 Q5BJF2 1/20 0.72
SIGMAR1 Q99720 1/20 0.72
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012357 0.93 CYP3A4 (0.83) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1009439 0.93 CYP3A4 (1.00) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1011419 0.92 CYP3A4 (0.84) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1011286 0.92 CYP3A4 (0.84) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1010719 0.91 CYP3A4 (0.79) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1011327 0.91 CYP3A4 (0.91) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1009288 0.90 CYP3A4 (0.85) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1011673 0.90 FAAH (0.81) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1011240 0.90 CYP3A4 (0.79) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1011698 0.89 CYP3A4 (0.84) CYP3A4CYP2D6FAAHGABRA1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP claimed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US claimed
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC CYP3A4 303/4885CYP2D6 292/4885FAAH 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.